Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Associated Factors with the Severity of Hip Involvement in Spondyloarthritis and Efficacy of TNF α Inhibitors in these Patients

Author(s): Maroua Slouma, Safa Rahmouni*, Rim Dhahri, Elhem Cheour, Imen Gharsallah, Leila Metoui and Bassem Louzir

Volume 18, Issue 1, 2022

Published on: 26 November, 2021

Page: [58 - 63] Pages: 6

DOI: 10.2174/1573397117666211012110212

Price: $65

Abstract

Introduction: Hip involvement in patients with spondyloarthritis is responsible for disability and functional impairment. Its treatment is not codified. Our study aimed to determine the associated factors with moderate and severe hip involvement in spondyloarthritis patients. It also aimed to assess the efficacy of tumour necrosis factor inhibitors (TNFi) on hip disease.

Methods: We conducted a cross-sectional study, including 44 spondyloarthritis patients with hip involvement. Hip involvement was diagnosed based on radiographic findings. We assessed the following parameters: Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), patient global assessment (PGA), and Lequesne index. We compared these parameters and the mean radiographic joint space width between the time of the study to those right before the use of TNFi.

Results: Hip involvement was bilateral in 31 patients. The mean age was 44.56±12.21 years. There were 29 men. Severe and moderate involvement (BASRI-hip>3) was reported in 21 hips from 75 affected. These patients were older and had longer diagnosis delays than patients with BASRI- hip<3. They had a higher body mass index and more limited spine mobility (BASMI). Functional hip impairment assessed by the Lequesne index was higher in these patients. TNFi prescribed in 23 patients with hip involvement, led to an improvement in the Lequesne index (12.75 vs 7.5, p: 0.001) and PGA (7 vs 2, p: 0.001). However, the mean joint space width remained unchanged (3.8 vs 3.7mm, p: 0.532).

Conclusion: Our study showed that higher body mass and Lequesne indexes are associated with moderate and severe hip involvement. TNFi may improve both the Lequesne index and PGA and stabilize the radiological findings.

Keywords: Hip joint, spondylarthritis, tumor necrosis factor inhibitors, BASMI, lequesne index, TNFi.

« Previous Next »
[1]
Burki V, Gossec L, Payet J, et al. Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients. Clin Exp Rheumatol 2012; 30(4): 481-6.
[PMID: 22513241]
[2]
Scaramangas-Plumley D, Lee M, Rahbar MH, Gensler LS, Reveille JD, Weisman M. Hip disease treatment and progression in ankylosing spondylitis. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA 2016.
[3]
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68(6): 777-83.
[http://dx.doi.org/10.1136/ard.2009.108233] [PMID: 19297344]
[4]
Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70(1): 25-31.
[http://dx.doi.org/10.1136/ard.2010.133645] [PMID: 21109520]
[5]
MacKay K, Brophy S, Mack C, Doran M, Calin A. The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 2000; 27(12): 2866-72.
[PMID: 11128678]
[6]
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21(9): 1694-8.
[PMID: 7799351]
[7]
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286-91.
[PMID: 7699630]
[8]
Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68(1): 18-24.
[http://dx.doi.org/10.1136/ard.2008.094870] [PMID: 18625618]
[9]
Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987; 65: 85-9.
[http://dx.doi.org/10.3109/03009748709102182] [PMID: 3479839]
[10]
Konsta M, Sfikakis PP, Bournia VK, Karras D, Iliopoulos A. Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. Clin Rheumatol 2013; 32(8): 1229-32.
[http://dx.doi.org/10.1007/s10067-013-2263-x] [PMID: 23604596]
[11]
Jeong H, Eun YH, Kim IY, et al. Characteristics of hip involvement in patients with ankylosing spondylitis in Korea. Korean J Intern Med (Korean Assoc Intern Med) 2017; 32(1): 158-64.
[http://dx.doi.org/10.3904/kjim.2015.229] [PMID: 27017388]
[12]
Brophy S, Mackay K, Al-Saidi A, Taylor G, Calin A. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 2002; 29(6): 1236-43.
[PMID: 12064842]
[13]
Guan M, Wang J, Zhao L, Xiao J, Li Z, Shi Z. Management of hip involvement in ankylosing spondylitis. Clin Rheumatol 2013; 32(8): 1115-20.
[http://dx.doi.org/10.1007/s10067-013-2278-3] [PMID: 23624589]
[14]
Calin A, Elswood J. The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis--one disease process or several? Br J Rheumatol 1988; 27(5): 393-5.
[http://dx.doi.org/10.1093/rheumatology/27.5.393] [PMID: 3179629]
[15]
Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995; 22(2): 241-5.
[PMID: 7738945]
[16]
Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005; (2): CD004800.
[PMID: 15846731]
[17]
Wendling D, Lukas C, Prati C, et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine 2018; 85(3): 275-84.
[http://dx.doi.org/10.1016/j.jbspin.2018.01.006] [PMID: 29407043]
[18]
Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the american college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) 2019; 71(10): 1285-99.
[http://dx.doi.org/10.1002/acr.24025] [PMID: 31436026]
[19]
Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007; 66(8): 1072-7.
[http://dx.doi.org/10.1136/ard.2006.064543] [PMID: 17261531]
[20]
Wang D, Ma L, Wu D. Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine 2011; 78(5): 531-2.
[http://dx.doi.org/10.1016/j.jbspin.2011.03.023] [PMID: 21570332]
[21]
Lian F, Yang X, Liang L, et al. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 2012; 32(6): 1663-7.
[http://dx.doi.org/10.1007/s00296-011-1844-8] [PMID: 21387110]
[22]
Petrov A, Zayaeva H, Petrov A. THU0355 Influence of adalimumab and sulfasalazine on structure of hyaline cartilage of hip joints in patients with ankylosing spondilitis. Ann Rheum Dis 2017; 76(Suppl. 2): 339-9.
[23]
Song R, Chung SW, Lee S-H. Radiographic evidence of hip joint recovery in patients with ankylosing spondylitis after treatment with anti-tumor necrosis factor agents: a case series. J Rheumatol 2017; 44(11): 1759-60.
[http://dx.doi.org/10.3899/jrheum.161401] [PMID: 29093078]

Rights & Permissions Print Cite
Article Metrics
31
1
World Hemophilia Day
© 2024 Bentham Science Publishers | Privacy Policy